ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1386	National Cancer Institute	Html	en	Delirium (PDQ®)–Health Professional Version	Expert-reviewed information summary about delirium as a complication of cancer or its treatment. Supportive care and pharmacologic approaches to the management of delirium are discussed.	elderly patients 0.428132 palliative medicine 0.41962 Fainsinger RL 0.451294 cancer center 0.422328 parent opioid compound 0.416673 palliative sedation. 0.469946 terminal sedation 0.549416 advanced cancer patients 0.459954 health care personnel 0.42512 QTc prolongation 0.496258 intravenous haloperidol 0.415462 risk factors 0.405793 refractory delirium 0.559163 oral opioid doses 0.440498 patients 0.718812 cancer patients 0.560957 sedation management. 0.490138 Lawlor PG 0.441422 palliative sedation therapy 0.708844 hypoactive delirium 0.522797 Palliat Care 0.456046 Pain Symptom Manage 0.718675 deep palliative sedation 0.612386 et al. 0.454631 study 0.418964	opioid toxicity 0.40801 deep sedation 0.500093 palliative care 0.916963 PUBMED Abstract 0.605152 agitated delirium 0.529672 haloperidol 0.510465 Opioid rotation section 0.412964 Support Care Cancer 0.588217 terminally ill patients 0.594369 delirium 0.992491 palliative sedation 0.977292 palliative care support 0.490339 Delirium reversal 0.553183 advanced cancer 0.474165 acute palliative care 0.478818 palliative care patients 0.570294 Palliat Med 0.428812 ill cancer patients 0.443961 palliative care experience 0.501267 palliative care unit 0.618846 palliative care units 0.586545 versus continuous sedation 0.526162 Injectable haloperidol 0.422082 palliative care programs 0.565085	CLICK HERE
1627	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Prevention (PDQ®)–Patient Version	Hepatitis B and C, cirrhosis, and aflatoxin (poison from certain foods) are important risk factors for liver cancer. Learn about all of the risk factors for liver cancer and how to prevent liver cancer in this expert-reviewed summary.	hepatocellular) cancer: 0.61402 cancer risk factors 0.453697 Cancer prevention 0.626716 cancer prevention trials 0.490017 Hepatitis viruses 0.484698 hepatitis G virus 0.482783 cancer protective factor 0.439442 hepatitis B virus 0.48738 hepatitis infection 0.475638 hepatitis B. 0.524229 protective factors 0.458515 following PDQ summaries 0.446108 Cancer Information Service 0.428793 PDQ cancer information 0.628691 hepatitis E virus 0.48361 prevention clinical trials 0.441049 acute hepatitis 0.480938 Hepatitis A vaccine 0.480499 Prevention Editorial Board 0.442759 hepatitis C virus 0.486051 National Cancer Institute 0.524466 clinical trials 0.620519 especially hepatitis 0.473486	cancer information summary 0.538122 risk factors 0.559595 breast cancer prevention 0.419616 hepatitis virus 0.531251 hepatitis B vaccine 0.480451 liver cancer prevention 0.489862 Cancer Care page 0.416878 PDQ database 0.39653 hepatitis C. 0.481259 cancer risk factor 0.462005 hepatitis 0.804007 NCI’s PDQ 0.403154 PDQ summary 0.417038 hepatitis A virus 0.488307 NCI PDQ cancer 0.479454 chronic hepatitis 0.527021 cancer clinical trials 0.440605 hepatitis D virus 0.484344 hepatitis B infection 0.473174 healthy liver tissue 0.433816 cancer information summaries 0.436678 comprehensive cancer information 0.436454 cancer 0.929112	CLICK HERE
1651	National Cancer Institute	Html	en	Milk Thistle (PDQ®)–Patient Version	Expert-reviewed information summary about the use of milk thistle as a treatment for people with cancer.	cancer treatment 0.701214 advanced liver cancer 0.66555 PDQ cancer information 0.729457 Cancer Complementary 0.666923 clinical trials 0.798052 U.S. Food 0.649163 cancer information summary 0.699946 alternative cancer therapies 0.663524 clinical trial 0.731299 CAM cancer research 0.657056 patients 0.673877 cancer patients 0.654835 randomized clinical trial 0.683387 Marian thistle 0.690666 NCI PDQ cancer 0.677418 cancer information database 0.662437 radiation therapy 0.660512 Therapies Editorial Board 0.664492 cancer information 0.734643 treatment 0.70795 cancer prevention 0.650452 Complementary Therapies Editorial 0.677699 United States 0.665688 Drug Administration 0.682045	Cancer Information Specialist 0.658528 cancer cells 0.669779 milk thistle supplements 0.741182 cancer cell lines 0.655527 anticancer medications 0.651405 Cancer Information Service 0.697895 CAM therapies 0.649867 treatment clinical trials 0.654645 National Cancer Institute 0.770559 alternative medicine 0.692591 conventional treatment 0.650077 St. Mary thistle 0.707197 Federal Trade Commission 0.651646 silymarin 0.670265 Cancer Care page 0.650369 breast cancer 0.668147 PDQ summary 0.650118 cancer clinical trials 0.667946 alternative therapies 0.674881 acute lymphoblastic leukemia 0.665296 neck cancer 0.65549 cancer information summaries 0.662842 colorectal cancer cells 0.652543 cancer 0.828322	CLICK HERE
1761	National Cancer Institute	Html	en	HIV Infection and Cancer Risk	A fact sheet that describes the increased risk of certain types of cancer by people infected with HIV.	HIV-infected persons 0.508754 Interagency HIV Study 0.502379 lung cancer 0.484047 B-cell non-Hodgkin lymphoma 0.458276 J. Hepatocellular cancer 0.468864 non-HIV cancer risk 0.494393 Cancer Specimen Resource 0.469635 HIV-infected populations 0.478653 AIDS Malignancy 0.457277 cervical cancer 0.693342 Cancer Match Study 0.479104 current HIV treatment 0.516027 cause liver cancer 0.489672 Shiels MS 0.582975 recent cancer trends 0.457251 Cancer Epidemiology 0.46223 cancers 0.670125 human immunodeficiency virus 0.500937 HIV-infected population 0.54327 HIV-infected people 0.947346 United States 0.521772 non–AIDS-defining cancers 0.549624 antiretroviral therapy 0.544479 non-Hodgkin lymphoma 0.547712 poorer cancer survival 0.482973	general population 0.519659 A. HIV infection 0.48948 Kaposi sarcoma 0.627254 anal cancers 0.515539 HIV-associated cancers 0.517566 AIDS-defining cancers 0.457988 National Cancer Institute 0.47979 substantially higher risk 0.462943 Silverberg MJ 0.555726 Hodgkin lymphoma 0.483616 AIDS Cancer Clinical 0.500517 higher risk 0.566781 HIV-infected individuals 0.743448 HIV-related cancers 0.456193 anal cancer 0.625604 HIV-infected women 0.50457 oral cavity/pharynx cancer 0.497269 cancer risk 0.617858 et al 0.549092 New England Journal 0.468444 cancer 0.93948 liver cancer 0.56236 appropriate cancer treatment 0.491194 HIV infection 0.611339	CLICK HERE
1814	National Cancer Institute	Html	es	Tratamiento del cáncer de esófago (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de esófago.	potentially operable carcinoma 0.227364 Compton CC 0.235729 gastric cardia carcinomas 0.224835 oesophageal cancer 0.276104 M0 TX 0.378744 largo plazo 0.224774 7th ed 0.235623 Oesophageal Cancer Followed 0.223828 Symptomatic gastroesophageal reflux 0.225069 ecografía endoscópica 0.322801 Estados Unidos 0.43962 mortalidad perioperatoria 0.229531 Natl Cancer Inst 0.232717 estadificación tnm 0.223626 La incidencia 0.230541 estadio iv 0.258573 M0 T2 0.809899 tumor.ampliar cáncer 0.321047 M0 T1 0.972287 Lerut A 0.228355 M0 T3 0.670603 estadio ib 0.273395 estadio ia 0.270617 células escamosas versus 0.290657 Van Cutsem E 0.252346	Estadio Grado Localización 0.256738 mucosa esofágica distal 0.27828 tumor.ampliar adenocarcinoma 0.241411 Cancer Staging Manual 0.279268 iia 1-x superior 0.228 Thorac Cardiovasc Surg 0.318859 estadio iiia 0.354448 PDQ Tratamiento 0.239147 New York 0.233171 invasive surgical staging 0.223534 estadio iiic 0.343305 estadio iia 0.319628 Cancer treatment 0.223659 Clin Oncol 0.262378 medio t2–3 0.237546 Byrd DR 0.234186 M1 TX 0.23325 American Joint Committee 0.2654 Thorac Surg 0.250251 M0 Tis 0.325056 positron emission tomography 0.377883 Am Coll Surg 0.230102 M0 T4a 0.550107 AJCC Cancer Staging 0.282666	CLICK HERE
1835	National Cancer Institute	Html	es	Tratamiento del mesotelioma maligno (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer del mesiotelioma maligno.	advanced malignant 0.116955 Cancer Res Clin 0.143881 unresectable malignant mesothelioma 0.113438 malignant mesothelioma previously 0.112719 Lung Cancer Study 0.118498 Leukemia Group 0.124194 Venkatraman E 0.115582 therapy with induction 0.114339 Antman KH 0.111559 Vogelzang NJ 0.12467 systemic chemotherapy 0.119496 patients with mesothelioma 0.113972 Thorac Oncol 0.117632 malignant mesothelioma 0.548307 with induction chemotherapy 0.120652 cisplatino versus 0.116229 Res Clin Oncol 0.141606 mesotelioma sarcomatoide 0.113237 intraperitoneal chemotherapy as 0.127133 patients with 0.17944 Union Against Cancer 0.114155 chemotherapy followed 0.119996 cisplatin-based intraperitoneal chemotherapy 0.127819 Lung Cancer 0.119323 multimodality approach 0.111112	PDQ Síndromes cardiopulmonares 0.116256 pleural maligno difuso 0.117211 Rusch VW 0.116274 patients with malignant 0.151958 National Cancer Institute 0.112603 induction chemotherapy followed 0.11661 Thorac Cardiovasc Surg 0.13604 Trimodality therapy with 0.114339 malignant pleural mesothelioma 0.977908 malignant peritoneal mesothelioma 0.154368 Clin Oncol 0.739133 extrapleural pneumonectomy 0.187603 diagnosed pleural mesothelioma 0.118912 DeCamp M 0.110451 pleural mesothelioma using 0.118896 cisplatino pemetrexed 0.111439 chemotherapy as treatment 0.13551 treated patients with 0.113408 advanced malignant mesothelioma 0.112494 Mentzer SJ 0.110243 European Organization 0.127591 Thorac Surg 0.114739 diffuse malignant mesothelioma 0.138575 pleural malignant 0.119345	CLICK HERE
1987	National Cancer Institute	Html	es	Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles.	sumario versa 0.501558 siguientes procedimientos 0.502311 células madre 0.524991 efectos secundarios meses 0.503043 siguientes aspectos 0.500523 años edad 0.500492 tratamiento mejora 0.501438 dosis pequeñas administras 0.501281 PDQ Descripción 0.501938 sección información 0.50094 efectos tardíos 0.505196 carcinoma nevoide 0.50085 PDQ Tumores 0.506016 PDQ Efectos tardíos 0.501814 líquido cefalorraquídeo 0.521206 punción espinal.Ampliar 0.500903 National Cancer Institute 0.5005 tumores benignos 0.508351 siguientes riesgos 0.500413 médula ósea.ampliar aspiración 0.502403 Instituto Nacional 0.501732	PDQ Tratamiento 0.505028 presente sumario 0.501062 determinados cambios 0.501002 riesgo promedio 0.513411 nuevos tipos 0.500625 riesgo alto.Riesgo promedio 0.501723 sistema nervioso central 0.814928 Physician Data Query 0.50178 brain tumor 0.501055 prueba irm 0.500762 Aboutâ„¢ Brain Tumors 0.500627 siguientes enfermedades 0.501038 cuánto tumor 0.503396 tumores embrionarios 0.994005 imágenes seguirán 0.500378 Cuánto tiempo 0.500383 siguientes enlaces 0.500476 SNC infantil recidivantes 0.502864 Brain Tumor Consortium 0.501941 infantil recidivantes 0.502523 siguientes pruebas 0.501153	CLICK HERE
16833	National Cancer Institute	Html	en	News and Events	The latest news from the Office of Cancer Nanotechnology Research and the Alliance, as well as upcoming and past events attended by the Office of Cancer Nanotechnology Research staff, and relevant upcoming scientific meetings.	National Cancer Institute 0.924974		CLICK HERE
16867	National Cancer Institute	Html	null	Cómo encontrar a un doctor o un establecimiento de tratamiento si usted tiene cáncer	Hoja informativa que ofrece sugerencias para escoger a un médico y un establecimiento para el tratamiento del cáncer.			CLICK HERE
17170	National Cancer Institute	Html	es	PC-SPES (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Hsieh TC 0.512609 cell lines 0.580614 DiPaola RS 0.518041 herbal compound 0.512202 cell cycle arrest 0.510653 Panax ginseng 0.534566 androgen-dependent lncap cells 0.510949 herbal formulation 0.520455 próstata lncap 0.510141 herbal combination 0.538545 Cancer Res 0.532897 Cancer Prev 0.510115 PC-SPES which 0.510153 PSA Rising 0.510712 Estados Unidos 0.514599 Natl Cancer Inst 0.529649 Pirani JF 0.524938 LNCaP cells 0.518113 pc-spes contenía des 0.513216 patients with 0.561272 In vitro mechanism 0.515105 Taille A 0.52428 Scutellaria baicalensis 0.522111 prostate carcinoma 0.52183 panax ginseng c.a 0.528442	George DJ 0.512309 herbal compound pc-spes 0.515596 Oh WK 0.520298 Nutr Cancer 0.510533 Hayek OR 0.509996 Glycyrrhiza uralensis 0.513578 using pc-spes 0.518341 células lncap 0.515795 Serenoa repens 0.547922 Ganoderma lucidum 0.527517 PC-SPES demostró actividad 0.512446 cell cycle 0.533145 PC SPES 0.530969 herbal composition pc-spes 0.529409 Buttyan R 0.516728 vitro toxicity mediated 0.512005 recent clinical trials 0.523629 Prostate Cancer Survivor 0.513926 herbal therapy pc-spes 0.566579 herbal supplement pc-spes 0.555382 Chinese herbal 0.520945 prostate cancer 0.978435 datos probatorios 0.516673 in vitro 0.808088	CLICK HERE